Brooks Laboratories Limited — Important, 28-02-2025: General Updates

Brooks Laboratories Limited has revised its integrated financials for the quarter and nine months ended December 31, 2024, addressing an error caused by a technical glitch during PDF conversion. The updated submission reflects accurate standalone and consolidated financial figures, which align with previously published details.

In terms of financial performance, the company reported revenue from operations of ₹20.52 crore and ₹59.24 crore for the quarter and nine months, respectively. Total income registered at ₹20.54 crore and ₹59.50 crore for the same periods. Despite a slight increase in expenditures, the profit before tax for the quarter stood at ₹0.94 crore, improving from ₹0.80 crore in the prior year. The consolidated figures displayed a loss before tax of ₹21.32 crore for the quarter. Proceeds from a recent preferential share issue amounting to ₹4,322.34 lakh will be utilized for investment in its joint venture, Brooks Steriscience Limited.

The financial adjustments and strategic moves suggest a cautious yet positive outlook for Brooks Laboratories, but stakeholders should monitor the ongoing execution of its investment strategy closely.